INCY vs LIXT · P/E 14, rev $5.14B vs $121.0M cap
Incyte Corporation (INCY) versus Lixte Biotechnology Holdings Inc (LIXT) — a side-by-side from cached financials, not a winner call.
Incyte Corporation (INCY) is a biotechnology company listed on US.
Lixte Biotechnology Holdings Inc (LIXT) is a biotechnology company listed on NASDAQ.
Latest reported INCY revenue for 2025-12-31 was $5.14B. Net income was $1.29B. Revenue was up 21.2% from 2024-12-31 to 2025-12-31. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
LIXT does not have a complete income-statement cache yet.
INCY currently screens at market cap $20.45B and trailing P/E 14.5. LIXT currently screens at market cap $121.0M.
Not investment advice. Open the INCY and LIXT stock pages for the full models.
Not investment advice.